|Placebo (N = 207)||ARISTADA 441 mg monthly (N = 207)||ARISTADA 882 mg monthly (N = 208)|
|0.02 lb||1.6 lb||1.9 lb|
- In the 12-week, placebo-controlled, fixed-dose schizophrenia trial, the percentage of patients with ≥7% increase in weight noted at the last post-baseline visit during the treatment period was 6% for placebo (N = 207), 10% for ARISTADA® (aripiprazole lauroxil) 441 mg monthly (N = 207), and 9% for ARISTADA 882 mg monthly (N = 208)2
References: 1. Nasrallah HA, Newcomer JW, Risinger R, et al. Effect of aripiprazole lauroxil on metabolic and endocrine profiles and related safety considerations among patients with acute schizophrenia. J Clin Psychiatry. 2016;77(11):1519-1525. 2. ARISTADA [package insert]. Waltham, MA: Alkermes, Inc; 2018.